These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 10565205)

  • 21. [Tuberculosis in 1989].
    Dautzenberg B; Broussier PM
    Rev Mal Respir; 1989; 6(1):3-4. PubMed ID: 2928582
    [No Abstract]   [Full Text] [Related]  

  • 22. [Drug resistance in Mycobacterium tuberculosis: diagnostic methods].
    Loïez-Durocher C; Vachée A; Lemaitre N
    Ann Biol Clin (Paris); 2000; 58(3):291-7. PubMed ID: 10846233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Tuberculosis control in the North-West of Russia].
    Levashev IuN
    Probl Tuberk Bolezn Legk; 2003; (10):3-9. PubMed ID: 14669619
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implementation of fixed-dose combinations in tuberculosis control: outline of responsibilities.
    Chaulet P
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S353-7; discussion S381-7. PubMed ID: 10593717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment and prevention of tuberculosis in HIV-infected patients: CDC guidelines.
    AIDS Read; 1999 Aug; 9(5):316-8, 323-6. PubMed ID: 12737121
    [No Abstract]   [Full Text] [Related]  

  • 26. [Work of the tuberculosis control service in the Ryazan Region under changing socioeconomic and epidemic conditions].
    Isakov SA; Makarova VG; Savkin AP; Dobin VL
    Probl Tuberk; 2002; (6):18-20. PubMed ID: 12227043
    [No Abstract]   [Full Text] [Related]  

  • 27. [The costs of anti-tuberculous chemotherapy (author's transl)].
    Sighart H
    Prax Klin Pneumol; 1978 Mar; 32(3):181-3. PubMed ID: 652714
    [No Abstract]   [Full Text] [Related]  

  • 28. Economic evaluation of public-private mix for tuberculosis care and control, India. Part II. Cost and cost-effectiveness.
    Pantoja A; Lönnroth K; Lal SS; Chauhan LS; Uplekar M; Padma MR; Unnikrishnan KP; Rajesh J; Kumar P; Sahu S; Wares F; Floyd K
    Int J Tuberc Lung Dis; 2009 Jun; 13(6):705-12. PubMed ID: 19460245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Old and new drugs for the treatment of tuberculosis in children.
    Donald PR; Schaaf HS
    Paediatr Respir Rev; 2007 Jun; 8(2):134-41. PubMed ID: 17574157
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Outlooks for promoting antituberculosis care for the Siberian population].
    Krasnov VA; Kalachev IV; Stepanov DV; Svistel'nik AV; Reviakina OV; Pogozheva LM
    Probl Tuberk Bolezn Legk; 2003; (5):3-6. PubMed ID: 12899004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trends in the use of antituberculosis drugs in Spain 1993-1998.
    Blázquez A; Arias J; Mateos-Campos R
    Pharmacoepidemiol Drug Saf; 2003; 12(3):227-36. PubMed ID: 12733476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Costs of investigating and managing non-residents with possible tuberculosis: New Zealand experience of an international problem.
    Burns AD; Harrison AC
    Respirology; 2007 Mar; 12(2):262-6. PubMed ID: 17298460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The economic aspects of the system of organizing antitubercular measures in Tomsk Province].
    Polivakho VV; Sharaburova OE
    Probl Tuberk; 2000; (5):32-5. PubMed ID: 11077849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary resistance to antituberculosis drugs: trends in Cote d'Ivoire from 1995 to 2006.
    N'guessan K; Dosso M; Nahoua I; Koffi MS; Kouakou J
    Med Mal Infect; 2008 Apr; 38(4):231-2. PubMed ID: 18262379
    [No Abstract]   [Full Text] [Related]  

  • 35. [Primary and acquired resistance to antituberculous drugs in strains of Mycobacterium tuberculosis isolated in Rwanda].
    Umubyeyi AN; Rigouts L; Zissis G; Kamanzi E; Pauwels P; Gasana M; Vandebriel G; Struelens M; Portaels F
    Med Trop (Mars); 2007 Apr; 67(2):149-53. PubMed ID: 17691433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tuberculosis drug resistance: a global threat.
    Nachega JB; Chaisson RE
    Clin Infect Dis; 2003 Jan; 36(Suppl 1):S24-30. PubMed ID: 12516027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Development of the cost of antitubercular drugs from 1964 to 1980: its influence on the choice of the treatment regimen tuberculosis in Algeria].
    Ait Khaled N; Oussedik N; Chaulet P
    Bull Int Union Tuberc; 1981; 56(3-4):170-4. PubMed ID: 7042012
    [No Abstract]   [Full Text] [Related]  

  • 38. [New-onset pulmonary tuberculosis patients with schizophrenia: course and efficiency of treatment].
    Mishin VIu; Shevchuk EIu; Tsygankov BD; Losev LV
    Probl Tuberk Bolezn Legk; 2008; (6):6-10. PubMed ID: 18710046
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapid DOTS expansion in India.
    Khatri GR; Frieden TR
    Bull World Health Organ; 2002; 80(6):457-63. PubMed ID: 12132002
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response to a major disease of poverty: the Global Partnership to Stop TB.
    Lee JW; Loevinsohn E; Kumaresan JA
    Bull World Health Organ; 2002; 80(6):428. PubMed ID: 12131996
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.